Spectral AI Appoints ‘High-Impact’ Healthcare Exec to its Board of Directors

In September, the firm began trading on Nasdaq and secured a BARDA Project BioShield contract worth up to $149 million.

Spectral AI Inc. has appointed Deepak Sadagopan, MHCDS, to the board of directors of the Dallas-based artificial intelligence company focused on medical diagnostics for faster and more accurate treatment decisions in wound care.

Sadagopan is a “high-impact” healthcare executive with more than 25 years of senior leadership experience with top Fortune-rated corporations and aggressive startup environments, the company said.

“Deepak brings a wealth of knowledge and relevant experience to Spectral AI as we advance the DeepView System through late-stage development and launch,” CEO Wensheng Fan said in a statement. “This is a transformational period for our company. Deepak’s contributions will enable us to continue to accelerate our work in bringing our technology to doctors and patients in need. We welcome him to the board with great enthusiasm.”

Sadagopan brings expertise in healthcare technology and analytics along with a successful track record in product launches.

Currently, Sadagopan is the chief operating officer of Population Health at Providence St. Joseph Health, one of the largest healthcare systems in the U.S., where he leads population health initiatives across the system to transform care.

“This company is dedicated to using imaging technology and AI to bring faster and more accurate wound management treatment decisions to doctors. The DeepView System has the potential to improve the lives of countless individuals and strengthen public health system preparedness in the US to respond to mass casualty incidents,” Sadagopan said. “I am energized by this opportunity to help guide the company as it approaches the final development work needed to get the technology on the market.”

Sadagopan has held leadership roles with Quest Diagnostics, McKesson, and Edifecs.

Over the past eight years, Sadagopan has focused on working closely with payers and providers on the use of technology to drive business decisions making the transition from volume to value-based delivery models.

Spectral AI is a predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers.

The company said it is working to revolutionize the management of wound care by “Seeing the Unknown” with its DeepView System, a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention.

In September, Spectral MD made its debut on Nasdaq and secured a BARDA Project BioShield contract worth up to $149 million. The contract supports the advanced development of the DeepView System, an AI-driven device for imaging burn wounds, tailored for use in emergency and trauma centers.

Get on the list.
Dallas Innovates, every day.

Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.

One quick signup, and you’re done.  

R E A D   N E X T

  • "Since data is crucial for maintaining ongoing DEIB initiatives and dedication, Kanarys leads the way in establishing quantifiable DEIB strategies, thanks to its data-centric methodology aimed at creating a fairer future for all work settings," says Google CDO and Kanary's Board Member Melonie Parker.

  • AI Master's Degree UNT

    Innovators across North Texas and entrepreneurs all over the U.S. are racing to launch (and patent) the latest breakthrough AI. That can lead to IP policy issues as emerging tech hits the market. On February 8, the U.S. Patent and Trademark Office will a public meeting to discuss how to promote innovation in AI and Machine Learning tech, to be held virtually and in person at the Arts District Mansion in Dallas. "The takeaways will shape future work on AI and ET policy," says USPTO Director Kathi Vidal.

  • The request was made in an open letter signed by major players including Elon Musk, co-founder of OpenAI, the lab that created ChatGPT and GPT-4; Emad Mostaque, founder of the London-based Stability AI; and Apple co-founder Steve Wozniak. More than 1,000 artificial intelligence experts, researchers, and backers signed the letter, including academics from UT Dallas.

  • Spectral MD Holdings, founded over a decade ago, is a predictive analytics company focused on wound care treatment. It plans to delist from the AIM market and list on Nasdaq via a SPAC merger, operating as Spectral AI. The company’s AI-enabled FDA Breakthrough Designated DeepView platform uses AI algorithms and "difficult-to-duplicate" imaging technology to provide healing assessments.

  • Oscar, the AI-powered robotic trash can at AT&T's downtown Dallas HQ, can spot a recyclable in nothing flat. Developed by Vancouver, Canada-based Intuitive AI, the robot checks out any trash item you hold up to it and tells you whether it goes in its recycling, compost, or landfill bins.